anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

215,101-215,160 of 319,975

filter-aware
34
Includes three distinct charts: a dot plot for IC50, a bar chart for selectivity index, and a bar chart for brain penetrance.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
Nuvalent | Investor Presentation Deck | 39 slidesNuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
36
The slide uses a cascading hexagonal process flow to illustrate the methodology.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
37
The slide uses a timeline-style layout to track drug development progress from discovery through clinical phases.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
38
Includes a molecular structure visualization.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
39
Nuvalent | Investor Presentation Deck | 39 slidesNuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
01
Slide 1
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
02
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
03
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
04
The slide uses a visual association between the three executives and the logos of companies/products they have been associated with.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Team1 hit
05
The slide uses a timeline-style layout to represent drug development stages.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
06
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
Includes a molecular pathway diagram and a Western blot image as evidence.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide demonstrates superior tumor volume reduction by NXP800 compared to standard-of-care Cisplatin in both SKOV-3 and TOV-21G models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Includes a patient-derived xenograft (PDX) study workflow diagram and a tumor volume growth curve.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart shows tumor volume reduction over 28 days compared to vehicle control.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
Clinical trial NCT05226507 status update.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The visualization is a standard kinome tree map used in pharmaceutical research to demonstrate drug selectivity.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
16
Uses a structural biology diagram to illustrate mechanism of action.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
17
Includes a biological pathway diagram, microscopy images, and an IC50 dose-response curve.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
18
The charts demonstrate efficacy in specific cell lines (KYSE70 and Cal27) with known genetic alterations.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
Includes two distinct experimental setups: cell proliferation assays and mouse tumor growth models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
Clinical trial identifier NCT05873686 is provided.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
21
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
23
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
01
Slide 1
Nuwellis | Investor Presentation Deck | 29 slidesNuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
02
Nuwellis | Investor Presentation Deck | 29 slidesNuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
03
Nuwellis | Investor Presentation Deck | 29 slidesNuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
04
Nuwellis | Investor Presentation Deck | 29 slidesNuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
05
Includes headshots and titles for 8 executives.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
06
The slide uses a numbered list format to categorize the problem into four distinct areas: clinical outcomes, cost/length of stay, reimbursement losses, and readmission penalties.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Problem1 hit
07
Includes medical citations for each claim.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Problem1 hit
08
Includes medical citations at the bottom.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Problem1 hit
09
Includes a list of clinical citations at the bottom.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Solution1 hit
10
Uses a numbered process flow diagram to explain medical device operation.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
11
Includes citation references and a 'Newly published' callout for the Abington Hospital study.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
12
Includes logos for UChicago Medicine and Lenox Hill Hospital/Northwell Health.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
13
The slide uses a split-layout to contrast the problem (diuretic resistance) with the solution (ultrafiltration) supported by clinical evidence.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
14
Slide features a press release excerpt detailing the partnership.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
15
The slide uses a matrix-like layout to categorize market segments by time horizon.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Market Size1 hit
16
The chart is a Kaplan-Meier survival curve showing the impact of fluid overload on patient outcomes.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
17
Includes a testimonial from a NICU nurse practitioner.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
18
The slide highlights high survival rates, particularly in the <10kg group which traditionally receives no therapy.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
19
The slide uses a split-pane layout: left side for problem/market context, right side for product solution.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
20
The slide uses a funnel-like visual to aggregate market segments into a total TAM.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
21
The slide uses a process-like diagram to categorize the IP coverage across five key technology domains.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
22
The slide uses a color-coded legend to distinguish between clinical, commercial, product, and partnership milestones.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
23
Includes a 'Growth Agenda' list and financial status indicators (cash/debt).Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Financials1 hit
24
Nuwellis | Investor Presentation Deck | 29 slidesNuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
25
This is a mission statement slide.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
26
Nuwellis | Investor Presentation Deck | 29 slidesNuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
27
The slide uses a bulleted list to represent a timeline of corporate events.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
28
Includes a callout box at the bottom summarizing strategic goals.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
29
This slide serves as a technical appendix for market sizing claims made elsewhere in the deck.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
01
Slide 1
Old Second Bancorp | Investor Conference Presentation Deck | 21 slidesOld Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Is1 hit
02
Old Second Bancorp | Investor Conference Presentation Deck | 21 slidesOld Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Is1 hit